Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grand Pharmaceutical GroupCGPHF 86 ROC (Joel Greenblatt) % is 8.79% as of Dec. 2025, which is 85% below its 10-year median of 59.44. GuruFocus rates CGPHF with a GF Scoreâ„¢ of 86/100. The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 77.82% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Grand Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.79%.
The historical rank and industry rank for Grand Pharmaceutical Group's ROC (Joel Greenblatt) % or its related term are showing as below:
CGPHF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.7 Med: 59.44 Max: 88.86
Current: 34.83
During the past 13 years, Grand Pharmaceutical Group's highest ROC (Joel Greenblatt) % was 88.86%. The lowest was 16.70%. And the median was 59.44%.
CGPHF's ROC (Joel Greenblatt) % is ranked better than 77.82% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs CGPHF: 34.83
Grand Pharmaceutical Group (OTCPK:CGPHF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group ROC (Joel Greenblatt) % Chart
CGPHF vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's ROC (Joel Greenblatt) % falls into.
Grand Pharmaceutical Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 8.79% mean?
Grand Pharmaceutical Group (CGPHF) has a ROC (Joel Greenblatt) % of 8.79% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Grand Pharmaceutical Group and its competitors. This is 85% below median its historical median of 59.44. Over the past decade, Grand Pharmaceutical Group's ROC (Joel Greenblatt) % has ranged from 16.70 to 88.86. According to the industry distribution chart, Grand Pharmaceutical Group ranks #218 out of 983 companies in the Drug Manufacturers industry, placing it in the top 22.2%.
Is Grand Pharmaceutical Group's ROC (Joel Greenblatt) % too high?
Grand Pharmaceutical Group's current ROC (Joel Greenblatt) % of 8.79% is 85% below median its 10-year median of 59.44. Over the past 10 years, this metric has ranged from a low of 16.70 to a high of 88.86. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Grand Pharmaceutical Group's value of 8.79% is 23.3% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #218 out of 983 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #218 out of 983 companies for ROC (Joel Greenblatt) %. This places Grand Pharmaceutical Group in the top 22% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.46. Grand Pharmaceutical Group's value of 8.79% is 23.3% below this benchmark. Historically, Grand Pharmaceutical Group's own ROC (Joel Greenblatt) % has ranged from 16.70 to 88.86 over the past decade. While the company's 10-year median is 59.44 vs. the industry median of 11.46, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current ROC (Joel Greenblatt) % of 8.79% is 23.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current ROC (Joel Greenblatt) % is 8.79%, which is 85% below median its own 10-year median of 59.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current ROC (Joel Greenblatt) % of 8.79%. The current ROC (Joel Greenblatt) % is 8.79%, which is 85% below median its 10-year median of 59.44 and 23.3% below the Drug Manufacturers industry median of 11.46. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current ROC (Joel Greenblatt) % is 8.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 
